Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the company, Marketbeat ...

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review ...

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Drugs in the class of therapies called complement inhibitors are currently available for GA. Apellis Pharmaceuticals’ Syfovre won its FDA approval in 2023; later that year, Astellas Pharma’s ...